Table 1 Patient characteristics and operative details in both groups
From: Effects of an artificial pancreas on postoperative inflammation in patients with esophageal cancer
AP group | control group | p-value | |
|---|---|---|---|
Age* | 66 (47–86) | 71 (46–90) | 0.526 |
Sex | 0.588 | ||
Male Female | 20 (74.1%) 7 (25.9%) | 55 (79.7%) 14 (20.3%) | |
Diabetes Mellitus | 0.503 | ||
Present Absent | 2(7.4%) 25(92.6%) | 9(13.0%) 60(87.0%) | |
Neoadjuvant chemotherapy | 0.031 | ||
Performed Not performed | 14((51.9%) 13(48.1%) | 52(75.4%) 17(24.6%) | |
Tumor location | 0.218 | ||
Ce Ut Mt Lt Ae | 0 (0%) 5 (18.5%) 19 (70.3%) 3 (11.1%) 0 (0%) | 1 (1.4%) 13 (18.8%) 33 (47.8%) 20 (28.9%) 2 (2.9%) | |
Operative approach | 0.094 | ||
VATS Robot Open | 16(59.3%) 7(25.9%) 4(14.8%) | 54(78.3%) 7(10.1%) 8(11.6%) | |
Operation time (min) * | 589 (468–722) | 558 (393–958) | 0.1397 |
Estimated blood loss (mL) * | 262 (50–680) | 341 (50-1640) | 0.2608 |